<DOC>
	<DOCNO>NCT01768897</DOCNO>
	<brief_summary>This phase I trial study side effect best dose CPI-613 give together cytarabine mitoxantrone hydrochloride treat patient relapsed refractory acute myeloid leukemia . Drugs use chemotherapy , CPI-613 , cytarabine mitoxantrone hydrochloride , work different way stop growth cancer cell , either kill cell stop divide . CPI-613 may help cytarabine mitoxantrone hydrochloride work well make cancer cell sensitive drug</brief_summary>
	<brief_title>CPI-613 , Cytarabine , Mitoxantrone Hydrochloride Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety maximum tolerate dose ( MTD ) CPI-613 administer high dose cytarabine , mitoxantrone ( mitoxantrone hydrochloride ) . SECONDARY OBJECTIVES : I . To determine pharmacokinetics ( PKs ) CPI-613 follow intravenous ( IV ) administration combination high dose cytarabine mitoxantrone . II . To observe response rate ( complete response [ CR ] , complete response incomplete platelet recovery [ CRi ] partial response [ PR ] ) CPI-613 combination high dose cytarabine mitoxantrone . III . To observe overall survival patient treat CPI-613 combination high dose cytarabine mitoxantrone . OUTLINE : This dose-escalation study CPI-613 . Patients receive CPI-613 intravenously ( IV ) 2 hour day 1-5 , cytarabine IV 3 hour every 12 hour 5 dos begin day 3 , mitoxantrone hydrochloride IV 15 minute 1st , 3rd , 5th dos cytarabine . . Treatment repeat every 14 day 2 courses* absence disease progression unacceptable toxicity . NOTE : *Patients undergo second course therapy receive CPI-613 IV 2 hour day 1-3 , cytarabine IV 3 hour every 12 hour 5 dos begin day 2 , mitoxantrone hydrochloride IV 15 minute 1st 3rd dos cytarabine . After completion study treatment , patient follow 6 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Patients must histologically cytologically document relapsed and/or refractory acute myeloid leukemia Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 3 Expected survival &gt; 3 month Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must use accepted contraceptive method ( abstinence , intrauterine device [ IUD ] , oral contraceptive double barrier device ) , must negative serum urine pregnancy test within 1 week prior treatment initiation ; ( Note : Pregnant patient exclude effect CPI613 fetus unknown ) Fertile men must practice effective contraceptive method study period , unless documentation infertility exist Mentally competent , ability understand willingness sign inform consent form No radiotherapy , treatment cytotoxic agent ( except CPI613 ) , treatment biologic agent anticancer therapy within 2 week prior treatment CPI613 ; patient must fully recover acute , nonhematological , noninfectious toxicity prior treatment cytotoxic drug , radiotherapy anticancer modality ( return baseline status note recent treatment ) ; patient persist , nonhematologic , noninfectious toxicity prior treatment ≤ grade 2 eligible , must document Aspartate aminotransferase ( [ AST ] /serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 3 x upper normal limit ( UNL ) , alanine aminotransferase ( [ ALT ] /serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 3 x UNL ( = &lt; 5 x upper limit normal [ ULN ] liver metastasis present ) Bilirubin = &lt; 1.5 x UNL Serum creatinine = &lt; 1.5 mg/dL 133 μmol/L International Normalized Ratio INR must &lt; 1.5 Serious medical illness , significant cardiac disease ( e.g . symptomatic congestive heart failure , unstable angina pectoris , myocardial infarction within past 6 month , uncontrolled cardiac arrhythmia , pericardial disease New York Heart Association class III IV ) , severe debilitate pulmonary disease , would potentially increase patient ' risk toxicity Patients active central nervous system ( CNS ) epidural tumor Any active uncontrolled bleeding , patient bleed diathesis ( e.g. , active peptic ulcer disease ) Pregnant woman , woman childbearing potential use reliable mean contraception ( teratogenic potential CPI613 unknown ) Lactating female potential excretion CPI613 breast milk ( Note : Lactating female exclude effect CPI613 nursing child unknown ) Fertile men unwilling practice contraceptive method study period Life expectancy le 3 month Any condition abnormality may , opinion investigator , compromise safety patient Unwilling unable follow protocol requirement Patients large recurrent pleural peritoneal effusion require frequent drainage ( e.g . weekly ) ; patient amount clinically significant pericardial effusion Active heart disease include myocardial infarction within previous 6 month , symptomatic coronary artery disease , uncontrolled arrhythmia , symptomatic congestive heart failure Albumin &lt; 2.0 g/dL &lt; 20 g/L Evidence ongoing , uncontrolled infection Patients know human immunodeficiency virus ( HIV ) infection ; ( Note : Patients know HIV infection exclude patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy , may unknown dangerous drug interaction CPI613 antiretroviral agent use treat HIV infection ) Patients receive standard investigational treatment cancer , investigational agent indication within past 2 week prior initiation CPI613 treatment ( use Hydrea allow ) Patients receive immunotherapy type within past 4 week prior initiation CPI613 treatment Requirement immediate palliative treatment kind include surgery Patients receive chemotherapy regimen stem cell support previous 6 month A history additional risk factor torsade de pointes ( e.g. , clinically significant heart failure , hypokalemia , family history long QT syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>